GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (TSE:4568) » Definitions » COGS-to-Revenue

Daiichinkyo Co (TSE:4568) COGS-to-Revenue : 0.24 (As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co COGS-to-Revenue?

Daiichinkyo Co's Cost of Goods Sold for the three months ended in Mar. 2024 was 円104,562 Mil. Its Revenue for the three months ended in Mar. 2024 was 円428,419 Mil.

Daiichinkyo Co's COGS to Revenue for the three months ended in Mar. 2024 was 0.24.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Daiichinkyo Co's Gross Margin % for the three months ended in Mar. 2024 was 75.59%.


Daiichinkyo Co COGS-to-Revenue Historical Data

The historical data trend for Daiichinkyo Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co COGS-to-Revenue Chart

Daiichinkyo Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.35 0.35 0.34 0.28 0.26

Daiichinkyo Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 0.27 0.25 0.27 0.24

Daiichinkyo Co COGS-to-Revenue Calculation

Daiichinkyo Co's COGS to Revenue for the fiscal year that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=415322 / 1601688
=0.26

Daiichinkyo Co's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=104562 / 428419
=0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Daiichinkyo Co  (TSE:4568) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Daiichinkyo Co's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 104562 / 428419
=75.59 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Daiichinkyo Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Daiichinkyo Co (TSE:4568) Business Description

Traded in Other Exchanges
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

Daiichinkyo Co (TSE:4568) Headlines

No Headlines